{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:47:36Z","timestamp":1790189256296,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JFB"],"abstract":"<jats:p>Background: Medication-related osteonecrosis of the jaw (MRONJ) is drug-induced bone destruction that is exposed for a minimum of 6 to 8 weeks in patients who have not received head and neck radiotherapy and who have not been diagnosed with facial bone metastases. MRONJ treatment outcomes are unpredictable. Therefore, alternative treatment methods are being explored, such as blood-derived platelet-rich preparations enriched with growth factors, including advanced platelet-rich fibrin (A-PRF). The presence of growth factors may enhance healing and reduce post-procedure complications. There are no studies examining the effect of A-PRF on the healing of patients with MRONJ. The aim of this study was to retrospectively evaluate treatment outcomes of patients with MRONJ surgically treated without and with the use of A-PRF. Materials and methods: This retrospective study included 28 patients who suffered from osteomyelitis due to MRONJ and underwent surgical treatment between 2019 and 2024. The patients were divided into two groups: the first group received surgical treatment without A-PRF, and the second group received surgical treatment with the application of A-PRF. This study analyzed demographic and clinical data, as well as treatment outcomes. Results: The patients were aged from 43 to 82 years. The most common cause of MRONJ was the administration of zoledronic acid for oncological reasons (22 patients, 78.6%), given intravenously. In 20 patients (71.4%), the antiresorptive treatment lasted longer than three years. The obtained healing distribution was binomial (presence or absence of healing). Estimation of the probability of healing using the maximum likelihood method provided a result of approximately 64%. The probability of ten or more healed patients in the A-PRF group was 41%. A-PRF helps with a probability of 59%, and without A-PRF, it was lower. Concomitantly, the differences between the group with A-PRF and without A-PRF were not statistically significant. Conclusions: The patients with MRONJ should have regular check-ups with radiological examinations at least every six months to detect possible recurrence. Treatment for MRONJ is long and difficult. Treatment of non-advanced lesions, without additional risk factors (such as treatment with zoledronate intravenously for oncological purposes for 3 years), showed a better prognosis. Sometimes, in addition to surgery, it is necessary to consider alternative methods. A-PRF may enhance MRONJ healing. However, there is no evidence of a significant effect of A-PRF on the healing of MRONJ.<\/jats:p>","DOI":"10.3390\/jfb16050180","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:27:41Z","timestamp":1747218461000},"page":"180","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of Medication-Related Osteonecrosis of the Jaw Without and With the Use of Advanced Platelet-Rich Fibrin: A Retrospective Clinical Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0514-4997","authenticated-orcid":false,"given":"Paulina","family":"Adamska","sequence":"first","affiliation":[{"name":"Division of Oral Surgery, Medical University of Gda\u0144sk, 7 D\u0119binki Street, 80-211 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5112-6322","authenticated-orcid":false,"given":"Marcin","family":"Stasiak","sequence":"additional","affiliation":[{"name":"Division of Orthodontics, Faculty of Medicine, Medical University of Gda\u0144sk, 42c Aleja Zwyci\u0119stwa, 80-210 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Kobusi\u0144ska","sequence":"additional","affiliation":[{"name":"University Dental Center, Medical University of Gda\u0144sk, 1a D\u0119bowa Street, 80-204 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0185-6460","authenticated-orcid":false,"given":"Micha\u0142","family":"Bartma\u0144ski","sequence":"additional","affiliation":[{"name":"Institute of Manufacturing and Materials Technology, Faculty of Mechanical Engineering and Ship Technology, Gda\u0144sk University of Technology, 11\/12 Gabriela Narutowicza Street, 80-233 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Zedler","sequence":"additional","affiliation":[{"name":"Division of Oral Surgery, Medical University of Gda\u0144sk, 7 D\u0119binki Street, 80-211 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9200-1320","authenticated-orcid":false,"given":"Micha\u0142","family":"Studniarek","sequence":"additional","affiliation":[{"name":"Department of Radiology, Faculty of Medicine, Medical University of Gda\u0144sk, 17 Smoluchowskiego Street, 80-210 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"ref_1","unstructured":"Marx, R.E. (2007). Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws. History, Etiology, Prevention, and Treatment, Quintessence Publishing Co., Inc."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"American Dental Association Council on Scientific Affairs (2006). Dental management of patients receiving oral bisphosphonatetherapy: Expert panel recommendations. J. Am. Dent. Assoc., 137, 1144\u20131150.","DOI":"10.14219\/jada.archive.2006.0355"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1601-0825.2007.01381.x","article-title":"Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis","volume":"14","author":"Sarin","year":"2008","journal-title":"Oral Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/j.bjoms.2013.09.008","article-title":"Osteonecrosis of the jaw related to everolimus: A case report","volume":"51","author":"Kim","year":"2013","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0022034515572021","article-title":"Infection and medication-related osteonecrosis of the jaw","volume":"94","author":"Katsarelis","year":"2015","journal-title":"J. Dent. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/2231-0762.178742","article-title":"Medication-related osteonecrosis of the jaw: Clinical and practical guidelines","volume":"6","author":"Rosella","year":"2016","journal-title":"J. Int. Soc. Prev. Community Dent."},{"key":"ref_8","first-page":"18","article-title":"The role of dental care providers in the management of patients prescribed bisphosphonates: Brief clinical guidance","volume":"66","author":"Abed","year":"2018","journal-title":"Gen. Dent."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Campisi, G., Mauceri, R., Bertoldo, F., Bettini, G., Biasotto, M., Colella, G., Consolo, U., Di Fede, O., Favia, G., and Fusco, V. (2020). Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17165998"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/oral2020014","article-title":"Osteonecrosis of Jaw Related to Bisphosphonates and Other Drugs\u2014Prevention, Diagnosis, Pharmacovigilance, Treatment: A 2021 Web Event","volume":"2","author":"Fusco","year":"2022","journal-title":"Oral"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"De Cicco, D., Boschetti, C.E., Santagata, M., Colella, G., Staglian\u00f2, S., Gaggl, A., Bottini, G.B., Vitagliano, R., and D\u2019amato, S. (2023). Medication-Related Osteonecrosis of the Jaws: A Comparison of SICMF\u2013SIPMO and AAOMS Guidelines. Diagnostics, 13.","DOI":"10.3390\/diagnostics13132137"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bovari-Biri, J., Miskei, J.A., Kover, Z., Steinerbrunner-Nagy, A., Kardos, K., Maroti, P., and Pongracz, J.E. (2025). Advancements in Bone Replacement Techniques\u2013Potential Uses After Maxillary and Mandibular Resections Due to Medication-Related Osteonecrosis of the Jaw (MRONJ). Cells, 14.","DOI":"10.3390\/cells14020145"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Laputkov\u00e1, G., Talian, I., and Schwartzov\u00e1, V. (2023). Medication-Related Osteonecrosis of the Jaw: A Systematic Review and a Bioinformatic Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316745"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Caggiano, M., Di Spirito, F., Acerra, A., Galdi, M., and Sisalli, L. (2023). Multiple-Drugs-Related Osteonecrosis of the Jaw in a Patient Affected by Multiple Myeloma: A Case Report. Dent. J., 11.","DOI":"10.3390\/dj11040104"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jobcr.2012.11.001","article-title":"Dental complications and management of patients on bisphosphonate therapy: A review article","volume":"3","author":"Kalra","year":"2012","journal-title":"J. Oral Biol. Craniofac. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1601-0825.2009.01568.x","article-title":"Bisphosphonate-related osteonecrosis: Genetic and acquired risk factors","volume":"15","author":"Sarasquete","year":"2009","journal-title":"Oral Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","article-title":"Medication-related osteonecrosis of the jaw: Definition and best practice for prevention, diagnosis, and treatment","volume":"127","author":"Mendes","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_19","first-page":"417","article-title":"A review of bisphosphonate-associated osteonecrosis of the jaws and its management","volume":"73","author":"Lam","year":"2007","journal-title":"J. Can. Dent. Assoc."},{"key":"ref_20","first-page":"37","article-title":"Guidelines for the diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ)","volume":"4","author":"Ruggiero","year":"2012","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tripleo.2006.12.004","article-title":"Bisphosphonates and osteonecrosis of the jaws: Science and rationale","volume":"104","author":"Gutta","year":"2007","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1259\/bjr\/99102700","article-title":"Skeletal complications of bisphosphonate use: What the radiologist should know","volume":"85","author":"Haworth","year":"2012","journal-title":"Br. J. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1148\/rg.2018170145","article-title":"Craniofacial manifestations of systemic disorders: CT and MR imaging findings and imaging approach","volume":"38","author":"Chapman","year":"2018","journal-title":"Radiographics"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ko, Y.Y., Yang, W.-F., and Leung, Y.Y. (2024). The Role of Cone Beam Computed Tomography (CBCT) in the Diagnosis and Clinical Management of Medication-Related Osteonecrosis of the Jaw (MRONJ). Diagnostics, 14.","DOI":"10.3390\/diagnostics14161700"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Berg, B.-I., Mueller, A.A., Augello, M., Berg, S., and Jaqui\u00e9ry, C. (2016). Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ). Dent. J., 4.","DOI":"10.3390\/dj4030029"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kojima, Y., Soutome, S., Otsuru, M., Hayashida, S., Sakamoto, Y., Sawada, S., and Umeda, M. (2022). Factors Exacerbating Clinical Symptoms and CT Findings in Patients with Medication-Related Osteonecrosis of the Jaw Receiving Conservative Therapy: A Multicenter Retrospective Study of 53 Cases. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19137854"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ibrahim, N., Apandi, N.I.M., Shuhardi, S.A., and Ramli, R. (2022). Actinomyces sp. Presence in the Bone Specimens of Patients with Osteonecrosis of the Jaw: The Histopathological Analysis and Clinical Implication. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081067"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ciobanu, G.A., Mogoant\u0103, L., Camen, A., Ionescu, M., Vlad, D., Staicu, I.E., Munteanu, C.M., Gheorghi\u021b\u0103, M.I., Mercu\u021b, R., and Sin, E.C. (2023). Clinical and Histopathological Aspects of MRONJ in Cancer Patients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103383"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chmielewski, M., Pilloni, A., and Adamska, P. (2024). Application of Advanced Platelet-Rich Fibrin in Oral and Maxillo-Facial Surgery: A Systematic Review. J. Funct. Biomater., 15.","DOI":"10.3390\/jfb15120377"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Adamska, P., Kaczoruk-Wieremczuk, M., Pyli\u0144ska-D\u0105browska, D., Stasiak, M., Bartma\u0144ski, M., Zedler, A., and Studniarek, M. (2024). Treatment of Oroantral Communication and Fistulas with the Use of Blood-Derived Platelet-Rich Preparations Rich in Growth Factors: A Systematic Review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111507"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Adamska, P., Pyli\u0144ska-D\u0105browska, D., Stasiak, M., Kaczoruk-Wieremczuk, M., Koz\u0142owska, E., Zedler, A., and Studniarek, M. (2024). Treatment of Odontogenic Maxillary Sinusitis with the Use of Growth Factors in Advanced Platelet-Rich Fibrin for Immediate Closure of Oro-Antral Communication: A Case Report. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25084339"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chmielewski, M., Pilloni, A., and Adamska, P. (2025). Advanced Platelet-Rich Fibrin Plus (A-PRF+) as an Additive to Hard Tissue Managing Protocols in Oral Surgery: A Systematic Review. J. Funct. Biomater., 16.","DOI":"10.3390\/jfb16040145"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Adamska, P., Pyli\u0144ska-D\u0105browska, D., Stasiak, M., Sobczak-Zagalska, H., Jusyk, A., Zedler, A., and Studniarek, M. (2024). Tooth Autotransplantation, Autogenous Dentin Graft, and Growth Factors Application: A Method for Preserving the Alveolar Ridge in Cases of Severe Infraocclusion\u2014A Case Report and Literature Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133902"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jcms.2016.05.004","article-title":"Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review","volume":"44","author":"Perez","year":"2016","journal-title":"J. Craniomaxillofac. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Frutuoso, F., Freitas, F., Vilares, M., Francisco, H., Marques, D., Caram\u00eas, J., and Moreira, A. (2024). Medication-Related Osteonecrosis of the Jaw: A Systematic Review of Case Reports and Case Series. Diseases, 12.","DOI":"10.3390\/diseases12090205"},{"key":"ref_36","unstructured":"Kaczmarczyk, T., Babiuch, K., Bo\u0142tacz-Rzepkowska, E., Dominiak, M., Konopka, T., Lipski, M., Olczak-Kowalczyk, D., Szel\u0105g, A., Szuta, M., and Hryniewicz, W. (2019). Rekomendacje Grupy Roboczej Polskiego Towarzystwa Stomatologicznego i Narodowego Programu Ochrony Antybiotyk\u00f3w w Zakresie Stosowania Antybiotyk\u00f3w w Stomatologii, Narodowy Instytut Lek\u00f3w."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10006-020-00831-0","article-title":"Laser surgery in management of medication-related osteonecrosis of the jaws: A meta-analysis","volume":"24","author":"Momesso","year":"2020","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.joms.2008.12.003","article-title":"Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Freiberger","year":"2009","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Nica, D.F., Rivi\u0219, M., Roi, C.I., Todea, C.D., Duma, V.-F., and Sinescu, C. (2021). Complementarity of Photo-Biomodulation, Surgical Treatment, and Antibiotherapy for Medication-Related Osteonecrosis of the Jaws (MRONJ). Medicina, 57.","DOI":"10.3390\/medicina57020145"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.oraloncology.2011.01.002","article-title":"Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study","volume":"47","author":"Ripamonti","year":"2011","journal-title":"Oral Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Kwon, Y.-D., and Kim, D.-Y. (2016). Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ). Dent. J., 4.","DOI":"10.3390\/dj4040041"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/jbmr.3237","article-title":"Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: A preliminary study","volume":"32","author":"Jung","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Colapinto, G., Goker, F., Nocini, R., Albanese, M., Nocini, P.F., Sembronio, S., Argenta, F., Robiony, M., and Del Fabbro, M. (2023). Outcomes of a Pharmacological Protocol with Pentoxifylline and Tocopherol for the Management of Medication-Related Osteonecrosis of the Jaws (MRONJ): A Randomized Study on 202 Osteoporosis Patients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144662"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Michalak, F., Dominiak, M., Kiryk, J., Popecki, P., Kubicki, D., Matys, J., and Grzech-Le\u015bniak, K. (2025). The Influence of Vitamin D Levels and Supplementation on the Treatment of Patients Affected by MRONJ. Appl. Sci., 15.","DOI":"10.3390\/app15020670"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pardo-Zamora, G., Mart\u00ednez, Y., Moreno, J.A., and Ortiz-Ru\u00edz, A.J. (2021). Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18031018"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e13334","DOI":"10.1111\/dth.13334","article-title":"Autologous platelet-rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication-related osteonecrosis of the jaw","volume":"33","author":"Bennardo","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105852","DOI":"10.1016\/j.oraloncology.2022.105852","article-title":"Osteonecrosis of the jaw induced by bisphosphonates therapy in bone metastases patient: Case report and literature review","volume":"128","author":"Hao","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jormas.2020.05.024","article-title":"Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF","volume":"122","author":"Bouland","year":"2021","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4103\/ijdr.IJDR_689_19","article-title":"Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the management of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report","volume":"31","author":"Giudice","year":"2020","journal-title":"Indian J. Dent. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s00784-016-2004-z","article-title":"Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: A trial study","volume":"21","author":"Asaka","year":"2017","journal-title":"Clin. Oral Investig."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Miranda, M., Gianfreda, F., Raffone, C., Antonacci, D., Pistilli, V., and Bollero, P. (2021). The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ). Biomed. Res. Int., 2021.","DOI":"10.1155\/2021\/4948139"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10006-023-01204-z","article-title":"The role of leukocyte and platelet-rich fibrin in the prevention of medication-related osteonecrosis of the jaw, in patients requiring dental extractions: An observational study","volume":"28","author":"Besi","year":"2024","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cre2.775","article-title":"Prevention and management of drug-induced osteonecrosis of the jaws using platelet-rich fibrin: A clinical feasibility study","volume":"9","author":"Alrmali","year":"2023","journal-title":"Clin. Exp. Dent. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10006-022-01094-7","article-title":"Efficacy of fibrin-rich platelets and leukocytes (L-PRF) in tissue repair in surgical oral procedures in patients using zoledronic acid-case-control study","volume":"27","author":"Parise","year":"2023","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_55","first-page":"e771","article-title":"Prevention of medication related osteonecrosis of the jaw after dentoalveolar surgery: An institution\u2019s experience","volume":"12","author":"Tatar","year":"2020","journal-title":"J. Clin. Exp. Dent."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jormas.2019.02.011","article-title":"The use of Platelet-rich Fibrin in the management of medication-related osteonecrosis of the jaw: A case series","volume":"121","author":"Capella","year":"2020","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.oooo.2018.06.007","article-title":"Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study","volume":"126","author":"Giudice","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_58","first-page":"811","article-title":"Platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: A clinical and histopathological evaluation","volume":"31","author":"Inchingolo","year":"2017","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"322","DOI":"10.5507\/bp.2020.023","article-title":"The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study","volume":"165","author":"Zelinka","year":"2021","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech Repub."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"\u00d6zalp, \u00d6., Y\u0131ld\u0131r\u0131myan, N., \u00d6zt\u00fcrk, C., Kocabalkan, B., \u015eim\u015fek Kaya, G., Sindel, A., and Altay, M.A. (2021). Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin. BMC Oral Health, 21.","DOI":"10.1186\/s12903-021-01965-7"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.joms.2016.12.005","article-title":"Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?","volume":"75","author":"Park","year":"2017","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s10006-024-01291-6","article-title":"The adjunctive use of Leukocyte-Platelet Rich Fibrin (L-PRF) in the management of Medication Related Osteonecrosis of the Jaw (MRONJ): A retrospective observational study","volume":"28","author":"Aslam","year":"2024","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/SCS.0000000000009161","article-title":"Use of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jaw","volume":"34","author":"Duygu","year":"2023","journal-title":"J. Craniofac. Surg."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tenore, G., Zimbalatti, A., Rocchetti, F., Graniero, F., Gaglioti, D., Mohsen, A., Caputo, M., Lollobrigida, M., Lamazza, L., and De Biase, A. (2020). Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113505"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Jamalpour, M.R., Shahabi, S., Baghestani, M., Shokri, A., Jamshidi, S., and Khazaei, S. (2022). Complementarity of surgical therapy, photobiomodulation, A-PRF and L-PRF for management of medication-related osteonecrosis of the jaw (MRONJ): An animal study. BMC Oral Health, 22.","DOI":"10.1186\/s12903-022-02275-2"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e8259","DOI":"10.1002\/ccr3.8259","article-title":"The use of advanced-platelet rich fibrin (A-PRF) in the management of medication-related osteonecrosis of the jaw (MRONJ): A case report","volume":"11","author":"Asfour","year":"2023","journal-title":"Clin. Case Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Roman, R.C., Moldovan, M.A., Pop, L.S., Megie\u0219an, S., and Faur, C.I. (2024). Platelet-Rich Fibrin Treatment Evaluation in Patients with Medication-Related Osteonecrosis of the Jaw and Osteoradionecrosis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13123473"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Blatt, S., Kr\u00fcger, M., K\u00e4mmerer, P.W., Thiem, D.G.E., Matheis, P., Eisenbei\u00df, A.-K., Wiltfang, J., Al-Nawas, B., and Naujokat, H. (2022). Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030682"}],"container-title":["Journal of Functional Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4983\/16\/5\/180\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:40Z","timestamp":1760031160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4983\/16\/5\/180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":68,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jfb16050180"],"URL":"https:\/\/doi.org\/10.3390\/jfb16050180","relation":{},"ISSN":["2079-4983"],"issn-type":[{"value":"2079-4983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}